Preliminary study on the correlation between grading and histology of solitary pulmonary nodules and contrast enhancement and $[^{18}F]$fluorodeoxyglucose standardised uptake value after evaluation by dynamic multiphase CT and PET/CT

Salvatore Cappabianca,1 Annamaria Porto,1 Mario Petrillo,1 Barbara Greco,1 Alfonso Reginelli,1 Francesco Ronza,1 Francesca Setola,1 Giovanni Rossi,2 Andrea Di Matteo,2 Roberto Muto,2 Maria Luisa De Rimini,2 Sergio Piccolo,3 Mara Catalano,3 Pietro Muto,3 Nicoletta De Rosa,4 Enrica Barra,4 Ilaria De Rosa,4 Francesca Antonolfi,4 Giuseppe Antonolfi,4 Mario Caputi,5 Luca Brunese,5 Roberto Grassi,1 Antonio Rotondo1

ABSTRACT

Aim To evaluate whether the histology and grading of solitary pulmonary nodules (SPNs) correlated with the results of dynamic multiphase multidetector CT (MDCT) and the $[^{18}F]$fluorodeoxyglucose standardised uptake value (SUV) in 30 patients.

Methods Chest x-rays of 270 patients with incidentally detected SPNs were retrospectively evaluated. Thirty patients with histologically proven SPNs were enrolled. On MDCT and positron emission tomography (PET)/CT images, two experts measured the density of nodules in all perfusion phases and the SUV. Net enhancement (NE) was calculated by subtracting peak pre-contrast density from peak post-contrast density. The Pearson test was used to correlate nodule NE, SUV, grading, histology and diameter.

Results Of the 30 malignant SPNs, six were classified as G1 (median NE, 31.5 Hounsfield units (HU); median SUV, 4.8 units), 15 were classified as G2 (median NE, 49 HU; median SUV, 6 units), and nine were classified as G3 (median NE, 58.5 HU; median SUV, 4.5 units). A highly negative correlation was found in G3 SPNs between NE and diameter.

Conclusions The significant correlation in dedifferentiated (G3) SPNs between NE and diameter supports the theory that stroma and neangiogenesis are fundamental in SPN growth. The highly negative correlation between NE and diameter demonstrates a net decrease in perfusion despite an increase in dimension. The multidisciplinary approach used herein may result in a more precise prognosis and consequently a better therapeutic outcome, particularly in patients with undifferentiated lung cancer.

INTRODUCTION

Characterisation of solitary pulmonary nodules (SPNs) is a major clinical and radiological concern; in fact, the overall incidence of malignancy in SPNs is 30–40% of cases.1–7 In the USA, ≈150,000 SPNs are detected each year with a progressive positive trend due to incidental findings on chest CT, which is widely used in oncological screening and follow-up.

SPNs are first detected on chest radiography. CT, $[^{18}F]$fluorodeoxyglucose (FDG) positron emission tomography (PET) and MRI are subsequently used to distinguish between benign and malignant nodules.8–12 The prevalence of malignancy in SPNs correlates with SPN dimensions: 0–1% in 5 mm nodules; 6–25% in nodules of 5–10 mm; 64–82% in nodules over 20 mm.2 Various radiological studies have shown that the histopathology of SPNs varies greatly, and malignancies account for about 60–80% of cases.6 13–15

The aim of this study was to evaluate whether there was a correlation between the histology and grading of SPNs and the results of dynamic multiphase multidetector CT (MDCT) and the $^{18}$F-FDG standardised uptake value (SUV) in 30 patients.

MATERIALS AND METHODS

The chest x-rays of 270 patients with incidentally detected SPNs (10–30 mm) were retrospectively evaluated. From these, the imaging sets of 153 patients who underwent MDCT and PET/CT within 30 days of chest x-rays were selected. Forty-eight of these patients had multiple lung nodules, whereas MDCT data were incomplete in 34. Forty-one SPNs <3 cm with a typical pattern of benign lesions such as macrocalcifications or a cystic pattern were excluded. Thus, 123 patients were excluded from the study. In conclusion, 30 patients (24 men, six women, mean age 67 years, range 54–86) were included in the study.

Image acquisition

All images were acquired with a 16-slice scanner (Brilliance 16; Philips, Eindhoven, The Netherlands).
Original article

using 120 kV, 300 mA, 16×1.25 pitch, 2 mm-thick slice and 1 mm gap. A pre-contrast acquisition followed by multiple post-contrast scans were obtained using dynamic acquisitions at 1, 2, 3 and 4 min after intravenous administration of 1.5 ml/kg non-ionic iodinated contrast medium (NICM; 350 mg/ml iodine). Three-dimensional PET was performed from feet to head 60 min after intravenous administration of 18F-FDG (4.5 MBq/kg). An integrated PET/CT scanner (Biograph 16; Siemens, Erlangen, Germany) consisting of an ultrafast CT scanner, with a 16-row multislice detector system, and a PET scanner, equipped with a full-ring lutetium oxyorthosilicate system and a crystal size of 4.4 mm², was used.

CT was performed in spiral mode. Data acquisition began with CT using 120 kV, 110–115 mA, 2 mm pitch and 1 s tube rotation, and these data were used for the correction of densitometric values of attenuation. Emission scan bed time was 3 min, resulting in a total PET scan time of 20–25 min (seven or eight bed positions), with axial image planes at a 16.2 cm axial field-of-view per position. After attenuation and scatter correction of PET data, images were reconstructed using an attenuation-weighted ordered-subsets maximisation expectation approach with two iterations and eight subsets on a 128×128 matrix and 5 mm Gaussian post-filtering.

Image analysis

All CT images were re-evaluated using a workstation, and densitometric measurements of SPNs were recorded in all contrastographic phases. To standardise recording values, a region of interest was drawn inside nodules, avoiding calcified inclusions, vessels, bronchogram or colliquative areas. Densitometry was evaluated along the equatorial plane of each lesion to cover almost 70% of the lesion. Net enhancement (NE) was evaluated by subtracting pre-contrast density from the peak density obtained from post-contrast values. PET/CT images were reconstructed on a Leonardo (Siemens Medical Solutions) workstation. A lesion was considered positive on the basis of visual judgement of the degree of increased glucose metabolism relating to mediastinum activity by two experienced, independent interpreters, supported by semiquantitative evaluation based on the calculation of the SUV of 18F-FDG-PET.

Statistical analysis

The correlation between dimensions, enhancement, SUV, grading and histological findings of SPNs was determined with the Pearson test; a correlation was defined when p<0.05 with 2 degrees of freedom.

RESULTS

As shown in table 1, morphological evaluation of SPNs revealed spiculated margins in 24/30 (72.8%) nodules and lobulated margins in 6/30 (26.2%). SPN diameter was 21–50 mm in 22/30 (73%) patients, 11–20 mm in 7/30 (23%) and <11 mm in 1/30 (4%). The median diameter of G1, G2 and G3 SPNs was 20.5 mm, 26 mm and 23 mm, respectively (figure 1). The histological diagnosis was lung cancer in all 30 patients: adenocarcinoma in 18/30 (60%) patients, epidermoid carcinoma in 6/30 (20%), carcinoid in 2/30 (6.7%), and small cell lung cancer in 4/30 (13.3%).

Of the 30 malignant SPNs, six were classified as G1 (well differentiatated (figure 2); median NE, 31.5 Hounsfield units (HU); 8.5 ± 12.5 SUV; 8 mm Gaussian post-filtering).

Table 1 Overview of the patients and tumours evaluated in this study

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Diameter (mm)</th>
<th>Histology</th>
<th>Pre-CT</th>
<th>Post-CT</th>
<th>NE</th>
<th>PET/SUV</th>
<th>Grade</th>
<th>Margins</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>20</td>
<td>Carcinoid</td>
<td>18</td>
<td>60</td>
<td>42</td>
<td>4.01</td>
<td>G1</td>
<td>Lobulated</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>20</td>
<td>Carcinoid</td>
<td>19</td>
<td>35</td>
<td>16</td>
<td>6.53</td>
<td>G1</td>
<td>Lobulated</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>22</td>
<td>Adenocarcinoma</td>
<td>25</td>
<td>83</td>
<td>58</td>
<td>7.14</td>
<td>G1</td>
<td>Spiculated</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>21</td>
<td>Adenocarcinoma</td>
<td>15</td>
<td>55</td>
<td>40</td>
<td>3.05</td>
<td>G1</td>
<td>Spiculated</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>22</td>
<td>Adenocarcinoma</td>
<td>10</td>
<td>26</td>
<td>16</td>
<td>4.50</td>
<td>G1</td>
<td>Spiculated</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>20</td>
<td>Adenocarcinoma</td>
<td>7</td>
<td>30</td>
<td>23</td>
<td>5.10</td>
<td>G1</td>
<td>Spiculated</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>14</td>
<td>Adenocarcinoma</td>
<td>27</td>
<td>54</td>
<td>27</td>
<td>6.03</td>
<td>G2</td>
<td>Spiculated</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>15</td>
<td>Adenocarcinoma</td>
<td>46</td>
<td>98</td>
<td>52</td>
<td>6.03</td>
<td>G2</td>
<td>Spiculated</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>29</td>
<td>Adenocarcinoma</td>
<td>50</td>
<td>105</td>
<td>55</td>
<td>6.03</td>
<td>G2</td>
<td>Spiculated</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>29</td>
<td>Adenocarcinoma</td>
<td>47</td>
<td>90</td>
<td>43</td>
<td>3.45</td>
<td>G2</td>
<td>Spiculated</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>30</td>
<td>Adenocarcinoma</td>
<td>47</td>
<td>69</td>
<td>47</td>
<td>3.67</td>
<td>G2</td>
<td>Spiculated</td>
</tr>
<tr>
<td>12</td>
<td>M</td>
<td>30</td>
<td>Adenocarcinoma</td>
<td>22</td>
<td>69</td>
<td>47</td>
<td>3.67</td>
<td>G2</td>
<td>Spiculated</td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>22</td>
<td>Adenocarcinoma</td>
<td>32</td>
<td>87</td>
<td>55</td>
<td>2.55</td>
<td>G2</td>
<td>Spiculated</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>25</td>
<td>Adenocarcinoma</td>
<td>28</td>
<td>58</td>
<td>30</td>
<td>5.80</td>
<td>G2</td>
<td>Spiculated</td>
</tr>
<tr>
<td>15</td>
<td>F</td>
<td>28</td>
<td>Adenocarcinoma</td>
<td>38</td>
<td>87</td>
<td>49</td>
<td>8.50</td>
<td>G2</td>
<td>Spiculated</td>
</tr>
<tr>
<td>16</td>
<td>M</td>
<td>26</td>
<td>Adenocarcinoma</td>
<td>48</td>
<td>65</td>
<td>17</td>
<td>4.40</td>
<td>G2</td>
<td>Spiculated</td>
</tr>
<tr>
<td>17</td>
<td>M</td>
<td>30</td>
<td>Epidermoid</td>
<td>34</td>
<td>86</td>
<td>52</td>
<td>38.22</td>
<td>G2</td>
<td>Spiculated</td>
</tr>
<tr>
<td>18</td>
<td>M</td>
<td>25</td>
<td>Epidermoid</td>
<td>17</td>
<td>82</td>
<td>65</td>
<td>10.20</td>
<td>G2</td>
<td>Spiculated</td>
</tr>
<tr>
<td>19</td>
<td>M</td>
<td>30</td>
<td>Epidermoid</td>
<td>75</td>
<td>98</td>
<td>23</td>
<td>19.50</td>
<td>G2</td>
<td>Spiculated</td>
</tr>
<tr>
<td>20</td>
<td>M</td>
<td>24</td>
<td>Epidermoid</td>
<td>42</td>
<td>102</td>
<td>60</td>
<td>2.10</td>
<td>G2</td>
<td>Spiculated</td>
</tr>
<tr>
<td>21</td>
<td>F</td>
<td>23</td>
<td>Epidermoid</td>
<td>39</td>
<td>60</td>
<td>21</td>
<td>22.40</td>
<td>G2</td>
<td>Spiculated</td>
</tr>
<tr>
<td>22</td>
<td>M</td>
<td>9.5</td>
<td>Adenocarcinoma</td>
<td>5</td>
<td>48</td>
<td>43</td>
<td>2.05</td>
<td>G3</td>
<td>Lobulated</td>
</tr>
<tr>
<td>23</td>
<td>M</td>
<td>22.5</td>
<td>Adenocarcinoma</td>
<td>12</td>
<td>44</td>
<td>32</td>
<td>12.50</td>
<td>G3</td>
<td>Lobulated</td>
</tr>
<tr>
<td>24</td>
<td>F</td>
<td>14</td>
<td>SCLC</td>
<td>57</td>
<td>94</td>
<td>37</td>
<td>0.10</td>
<td>G3</td>
<td>Lobulated</td>
</tr>
<tr>
<td>25</td>
<td>M</td>
<td>27</td>
<td>SCLC</td>
<td>25</td>
<td>47</td>
<td>22</td>
<td>5.50</td>
<td>G3</td>
<td>Lobulated</td>
</tr>
<tr>
<td>26</td>
<td>M</td>
<td>14</td>
<td>Adenocarcinoma</td>
<td>18</td>
<td>62</td>
<td>44</td>
<td>0.10</td>
<td>G3</td>
<td>Spiculated</td>
</tr>
<tr>
<td>27</td>
<td>M</td>
<td>28</td>
<td>Adenocarcinoma</td>
<td>43</td>
<td>69</td>
<td>26</td>
<td>8.13</td>
<td>G3</td>
<td>Spiculated</td>
</tr>
<tr>
<td>28</td>
<td>M</td>
<td>23</td>
<td>Adenocarcinoma</td>
<td>18</td>
<td>44</td>
<td>26</td>
<td>7.50</td>
<td>G3</td>
<td>Spiculated</td>
</tr>
<tr>
<td>29</td>
<td>M</td>
<td>27</td>
<td>SCLC</td>
<td>19</td>
<td>41</td>
<td>22</td>
<td>4.59</td>
<td>G3</td>
<td>Spiculated</td>
</tr>
<tr>
<td>30</td>
<td>M</td>
<td>26</td>
<td>SCLC</td>
<td>38</td>
<td>75</td>
<td>37</td>
<td>2.90</td>
<td>G3</td>
<td>Spiculated</td>
</tr>
</tbody>
</table>

E, net enhancement; SCLC, small cell lung cancer; SUV, standardised uptake value.
median SUV, 4.8 units (figures 3 and 4)), 15 were classified as G2 (moderately differentiated (figure 5); median NE, 49 HU; median SUV, 6 units (figures 3 and 4)), and nine were classified as G3 (poorly differentiated (figure 6); median NE, 32 HU; median SUV, 4.5 units (figures 3 and 4)). NE was >15 HU in all patients. SUV was <2.5 units in four patients and >2.5 units in 26 patients.

The Pearson correlation test revealed a highly negative correlation in G3 SPNs between NE and their corresponding diameters (r = -0.834 and p = 0.00524) (figure 7). Analysis of the correlation between SPN dimensions, NE, SUV, grading and histological findings showed that the NE of malignant SPNs increased with an increase in diameter (r = 0.982; p = 0.284). Also the SUV increased as the SPN diameter increased (r = 0.789; p = 0.421). In addition, NE and SUV were higher in G2 than G1 SPNs, and lower in G2 than G3 SPNs (r = 0.97; p = 0.137). p Values > 0.05 were probably due to the low number of patients enrolled in the study.

**DISCUSSION**

Evaluation of morphological aspects is usually the first step in diagnosing SPNs.\(^3\) Margins are considered important, usually being well defined in benign lesions and irregular and/or spiculated in malignant lesions. However, about 20–30% of SPNs with well-defined margins are diagnosed as malignant.\(^4\) \(^5\) Moreover, the margins of many nodules are classified as indeterminate, and diagnosis remains a dilemma.

---

**Figure 1** Median diameters of single pulmonary nodules according to grade.

**Figure 2** Adenocarcinoma in a 69-year-old woman. The post-contrast axial scan shows a transverse thin section (2.0 mm collimation) on a 20 mm nodule (arrow) with spiculated margins (A,B). After placement of a superimposed region of interest, the post-contrast image shows an enhancement of 30 Hounsfield units (HU) at 4 min and a net enhancement of 23 HU. The solitary pulmonary nodule has an area of \(^{18}\)F fluorodeoxyglucose uptake with a maximum standardised uptake value of 5.10 units; fusion images on axial sagittal and coronal planes show this captation area (C,D). This lesion was classified as a well-differentiated (G1) adenocarcinoma with low vascularity, poor necrosis and moderate cellularity (E).

**Figure 3** Net enhancement in G1, G2 and G3 single pulmonary nodules.
The advent of dynamic MDCT and PET/CT in the early 1990s represented a breakthrough in oncology, particularly with regard to identification and characterisation of SPNs. MDCT and PET/CT, unlike biopsy, videothoracoscopy and surgical resection, are non-invasive procedures. The rationale of this method is based on the abnormal and anarchic vascularisation of malignant SPNs that sustains the fast rate of tumour growth. CT scans with NICM readily detect vascular structures. The efficiency of dynamic CT in the characterisation of SPNs is well established, although different modalities of technical execution and cut-off values have been used to identify malignant SPNs. We carry out MDCT examinations using the protocol CT of Swensen et al and dynamic volumetric scans 1, 2, 3 and 4 min after NICM administration. This procedure has sensitivity, specificity and accuracy values of 98%, 58% and 77% in differentiating benign from malignant SPNs. It has been reported that scans acquired 15 min after NICM injection showed contrast medium washout, differentiating among benign nodules those with high enhancement, active granulomas and vascular lesions, and also differentiating among malignant nodules, thereby increasing specificity. However, despite potential benefit in terms of specificity, in order to limit the patients’ exposure to radiation, we did not carry out scans 15 min after NICM administration.

PET is a nuclear medicine technique based on the pharmacodynamics of the 18F-FDG radiotracer that enters neoplastic nodules. SUV is the ratio between the amount of radiotracer taken up by a lesion and the amount of radiotracer that would hypothetically be present in a region of equal volume if the tracer was uniformly distributed throughout the body. A SUV of >2.5 units is highly predictive of malignancy. At a SUV of ≥2.5 units, PET has a sensitivity and specificity of 77% and 100%, respectively. Very few studies have used SUV cut-offs of ≥3.5 and ≥5.5 units, which have lower sensitivity and specificity values than >2.5 or <2.5 units. Integrated with MDCT, PET has a sensitivity, specificity and accuracy of 96%, 88% and 93%, respectively, in identifying malignant SPNs. PET/CT alone cannot detect nodules of <1 cm, carcinoids or bronchioalveolar carcinomas. A strong correlation has recently been reported between contrast enhancement and microvessel density and between SUV and histological findings. Therefore, CT and PET/CT can play a relevant role in evaluating the response to treatment, particularly if considered together with histology and grading.

![Figure 4](image1.png) Median [18F]fluorodeoxyglucose standardised uptake value (SUV) in G1, G2 and G3 single pulmonary nodules.

![Figure 5](image2.png) Adenocarcinoma in a 79-year-old man. Post-contrast CT axial scan shows a transverse thin section (2.0 mm collimation) on a 30 mm nodule (arrow) with spiculated margins (A,B). A superimposed region of interest on post-contrast images at 4 min shows an enhancement of 87 Hounsfield units (HU) and a net enhancement of 55 HU. The solitary pulmonary nodule has an area of [18F]fluorodeoxyglucose uptake, with a maximum standardised uptake value of 2.55 units. The positron emission tomography image integrated with the CT image to obtain fusion images on axial sagittal and coronal planes shows the captation site (C,D). This lesion was classified as a moderately differentiated (G2) adenocarcinoma with rich vascularity, moderate necrosis, low hypercellularity and moderate connective stroma (E).

This is the first study to look at the relationship between CT enhancement, SUV and histopathological grading of SPNs. Grading is the most accurate biological indicator of disease activity and a fundamental prognostic factor because the degree of cellular differentiation predicts relapse and/or metastasis development. Patients with undifferentiated lung cancer were reported to have an 80% risk of death, whereas patients with poorly differentiated or moderately differentiated lung cancer have a risk of death of 70% and 40%, respectively.22

In our study, G2 SPNs were the largest lesions (median 26.5 mm), G1 were the smallest (median 20 mm) and G3 SPNs were slightly larger than G1 SPNs (median 23 mm) but smaller than G2 SPNs. Median NE and SUV were higher in G2 than G1 SPNs and lower in G3 than G2 SPNs. We found a significant negative correlation between NE and lesion diameter in G3 SPNs, demonstrating a net decrease of perfusion in dedifferentiated (G3) SPNs, particularly when compared with G2 SPNs. This observation supports the finding of Wang et al23 that CT enhancement may reflect tumour angiogenesis. In addition, as mentioned above, immunochemical studies have demonstrated a correlation between enhancement and microvessel density in SPNs.19 20 There are various reports of a significant decrease in microvessel density going from G1 to G3 renal cell carcinomas due to architectural remodelling of vascularity influenced by tumour progression.24–27 Diverse mechanisms have been evoked to explain this behaviour: the inability of neovascularisation to keep pace with a high proliferation of tumour cells causes a decrease in architectural complexity, and the tumour becomes hypoxic and necrotic; and the development of fibrosis and large vascular channels within the tumour would have the effect of decreasing microvessel density without necessarily altering the total vascular area and blood supply. According to Vaupel,28 the most highly vascularised regions within the tumour may not reflect the dedifferentiated grade: a relevant percentage of tumour vascularisation may be temporarily non-functional because of the development of thromboses and shunts. Similar physiopathological principles could explain the SUV trend identified in this study: cellular proliferation seems to be reduced with the decrease in vascular stroma and the increase in fibrosis, inducing a proportionally lower uptake of 18F-FDG, especially in G3 SPNs. However, while this mechanism could explain the lower SUV in G3 versus G2 SPNs, it does not explain the higher SUV in G2 versus G1 and G3 SPNs.

Figure 6  Adenocarcinoma in a 71-year-old man. Post-contrast CT axial scan shows a transverse thin section (2.0 mm collimation) on a 9.5 mm nodule (arrow) with lobulated margins (A,B). A superimposed region of interest shows an enhancement of 48 Hounsfield units (HU) and a net enhancement of 43 HU. The solitary pulmonary nodule has a standardised uptake value of 2.05 units; fusion images obtained on the axial sagittal and coronal planes show the captation areas (C,D). This lesion was classified as a poorly differentiated (G3) adenocarcinoma with moderate vascularity, low necrosis and hypercellularity and moderate connective stroma (E).

Figure 7  Scatterplot of the correlation between net enhancement (NE) and median diameter of G3 single pulmonary nodules.

In conclusion, our data on NE and SUV in G1, G2 and G3 SPNs support the theory that stroma and neoangiogenesis are fundamental in the growth of SPNs, above all in G3 SPNs where the highly negative correlation between NE and the corresponding diameters demonstrate a net decrease in perfusion despite the increase in dimensions.21 29 Our data indicate that the multidisciplinary approach used in this study may result in a more precise prognosis and consequently a better therapeutic outcome, particularly in patients with undifferentiated lung cancer. However, owing to the small number of patients in our study, it is difficult to identify clinically important results. Therefore, studies with larger numbers of patients and more histological subtypes are required to determine the full potential and clinical impact of the combined use of MDCT, PET/CT and grading in evaluating SPNs.

Acknowledgements We thank Jean Ann Gilder for revising and editing the text.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

Preliminary study on the correlation between grading and histology of solitary pulmonary nodules and contrast enhancement and $^{18}$F-fluorodeoxyglucose standardised uptake value after evaluation by dynamic multiphase CT and PET/CT

Salvatore Cappabianca, Annamaria Porto, Mario Petrillo, Barbara Greco, Alfonso Reginelli, Francesca Ronza, Francesca Setola, Giovanni Rossi, Andrea Di Matteo, Roberto Muto, Maria Luisa De Rimini, Sergio Piccolo, Mara Catalano, Pietro Muto, Nicoletta De Rosa, Enrica Barra, Ilaria De Rosa, Francesca Antinolfi, Giuseppe Antinolfi, Mario Caputi, Luca Brunese, Roberto Grassi and Antonio Rotondo

*J Clin Pathol* published online December 17, 2010

---

Updated information and services can be found at:

[http://jcp.bmj.com/content/early/2010/12/17/jcp.2010.076562](http://jcp.bmj.com/content/early/2010/12/17/jcp.2010.076562)

---

**References**

This article cites 29 articles, 2 of which you can access for free at:

[http://jcp.bmj.com/content/early/2010/12/17/jcp.2010.076562#BIBL](http://jcp.bmj.com/content/early/2010/12/17/jcp.2010.076562#BIBL)

**Open Access**

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: [http://creativecommons.org/licenses/by-nc/2.0/](http://creativecommons.org/licenses/by-nc/2.0/) and [http://creativecommons.org/licenses/by-nc/2.0/legalcode](http://creativecommons.org/licenses/by-nc/2.0/legalcode).

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

**Topic Collections**

Articles on similar topics can be found in the following collections

- Open access (122)
- Clinical diagnostic tests (805)
- Lung cancer (oncology) (120)
- Lung cancer (respiratory medicine) (120)

---

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)